As a downstream effector of interferon-gamma (IFN-γ), the antitumour activity of IP10 has been previously demonstrated in several cancer types, such as breast, B Burkitt lymphoma and myeloma21, 22, 23. This evidence concerns the gene IFNG and cancer.